The FDA has postponed its November meeting with drugmaker Perrigo about making birth control pills available over-the-counter, the company said Wednesday.
The FDA and Perrigo were expected to discuss Opill, a once-daily non-estrogen contraceptive, which is typically used with a prescription since its approval in 1973.
The company said the FDA postponed the meeting, which was originally scheduled for Nov. 18, to “review additional information” related to the switch from prescription to OTC. Perrigo said the health regulator has also extended the decision date for a possible approval decision by 90 days.
The rescheduled meeting date has not yet been determined, Perrigo said.
This comes four months after the Supreme Court overturned Roe v. Wade, sparking protests across Massachusetts and the U.S.
(Copyright (c) 2025 Sunbeam Television. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.)